Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome

American Journal of Clinical Dermatology

Volumn 7, Issue 6, 2006, Pages 359-368

  Mittmann, Nicole ^a   Chan, Brian ^a   Knowles, Sandra ^a   Cosentino, Lidia ^b   Shear, Neil ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b Talecris Biotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HUMAN IMMUNOGLOBULIN; IGIVNEX; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; ANAPHYLAXIS; ARTIFICIAL VENTILATION; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEMOLYSIS; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEPHROSIS; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; DOSE RESPONSE; DRUG ADMINISTRATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; STEVENS-JOHNSON SYNDROME;

EID: 34047267273     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200607060-00004     Document Type: Review

References (32)

1. Fritsch PO, Ruiz-Maldonado R. Stevens-Johnson syndrome: toxic epidermal necrolysis. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick's dermatology in general medicine. 5th ed. Toronto (ON): McGraw-Hill, 1999: 644-50
2. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993 Jan; 129 (1): 92-6
3. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002 Dec 24; 59 (12 Suppl. 6): S28-32
4. Talecris Biotherapeutics Inc. IGIVnex™ product monograph. Research Triangle Park (NC): Talecris Biotherapeutics Inc., 2006 Mar 3
5. Talecris Biotherapeutics Inc. Gamunex® product monograph. Research Triangle Park (NC): Talecris Biotherapeutics Inc., 2006 Feb 1
6. Baxter International Inc. Gammagard® SD product monograph. Deerfield (IL): Baxter International Inc., 2004 Jan 15
7. Baxter International Inc. Iveegam Immuno® product monograph. Deerfield (IL): Baxter International Inc., 2002 Jul
8. Siegel J. Immune globulins: therapeutic, pharmaceutical, & cost considerations. Pharmacy Practice News 2006 Jan
9. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990 Jan; 126 (1): 37-42
10. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991 Jun; 127 (6): 839-42
11. Naldi L, Locati F, Marchesi L, et al. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990 Aug; 126 (8): 1103-4
12. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990 Jan; 126 (1): 43-7
13. Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf 2004; 27 (7): 477-87
14. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005 Aug; 153 (2): 241-53
15. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 Sep 6; 345 (10): 747-55
16. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 Oct 16; 282 (5388): 490-3
17. Paquet P, Kaveri S, Jacob E, et al. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 2006 May; 15 (5): 381-6
18. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004 Jan-Feb; 25 (1): 81-8
19. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004 Nov; 43 (11): 847-51
20. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003 Jan; 139 (1): 33-6
21. Campione E, Marulli GC, Carrozzo AM, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003; 83 (6): 430-2
22. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005 Jun; 58 (4): 504-10
23. Nasser M, Bitterman-Deutsch O, Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci 2005 Feb; 329 (2): 95-8
24. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003 Jan; 139 (1): 26-32
25. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004 May-Jun; 25 (3): 246-55
26. Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203 (1): 45-9
27. Tan A, Tan HH, Lee CC, et al. Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins. Clin Exp Dermatol 2003 May; 28 (3): 269-71
28. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 2003 Jan; 139 (1): 39-43
29. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002 Oct; 47 (4): 548-52
30. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005 Nov-Dec; 71 (6): 398-400
31. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207 (1): 96-9
32. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg): clinical experience to date. Drugs 2005; 65 (15): 2085-90